NCT01185158 2023-11-29
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
University of Chicago
Phase 2 Completed
Clinical Trials
9 trialsNCT01185171 2023-05-11
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
University of Chicago
Phase 2 Completed
NCT00095836 2017-05-31
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Phase 2 Completed
NCT00519077 2016-07-01
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
University of Chicago
Phase 2 Completed
NCT00015964 2013-09-05
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
University of Chicago
Phase 2 Completed
NCT00352105 2012-11-05
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00193284 2010-06-22
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00185835 2010-03-29
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
Stanford University
Phase 1 Completed
NCT00195078 2007-07-20
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
Weill Medical College of Cornell University
Phase 1/2 Terminated